Retatrutide Side Effects and Safety Profile: What to Know
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Understanding retatrutide's safety profile is essential for informed decision-making. This article provides a thorough review of adverse events reported in Phase 1, 2, and 3 clinical trials, including gastrointestinal effects, cardiovascular considerations, and liver enzyme changes.
Retatrutide Safety Overview
As with any investigational drug, understanding the safety and tolerability profile of retatrutide is crucial. Data from Phase 1b, Phase 2, and early Phase 3 clinical trials provide a comprehensive picture of the drug's adverse event profile. Overall, retatrutide has demonstrated an acceptable safety profile consistent with its mechanism of action, though certain side effects warrant attention. For a deeper dive into this area, see peptide side effects and safety guide.
Gastrointestinal Side Effects
The most common adverse events with retatrutide are gastrointestinal (GI) in nature, consistent with the GLP-1 receptor agonist class. In the Phase 2 obesity trial [1]:
Nausea
Diarrhea
Vomiting
Constipation
Decreased Appetite
Dose Titration Mitigates GI Effects
The dose-escalation protocols used in clinical trials (starting at lower doses and gradually increasing) significantly reduce the incidence and severity of GI side effects. Most GI events occurred during the first few weeks of each dose increase and resolved with continued treatment.
---
> Ready to explore this therapy with expert guidance? The clinical team at Telegenix offers personalized peptide and TRT consultations backed by real lab work and evidence-based protocols. Book a free consultation today.
---
Discontinuation Rates
In the Phase 2 obesity trial, treatment discontinuation due to adverse events occurred in:
The higher discontinuation rate at 12 mg was primarily driven by GI intolerance. However, the majority of participants (84%) at the highest dose completed the full 48-week treatment.
Heart Rate Effects
Retatrutide was associated with small increases in resting heart rate, a class effect seen with GLP-1 receptor agonists:
Liver Enzyme Changes
Transient elevations in alanine aminotransferase (ALT) were observed in some participants, particularly at higher doses. These elevations are believed to be related to glucagon receptor-mediated increases in hepatic metabolic activity rather than hepatotoxicity:
Hypoglycemia
The risk of hypoglycemia with retatrutide is low when used without concomitant insulin or sulfonylureas. The glucose-dependent nature of GLP-1 and GIP-mediated insulin secretion provides a built-in safety mechanism. In the Phase 2 diabetes trial, clinically significant hypoglycemia was rare [3].
Injection Site Reactions
Mild injection site reactions (redness, itching, or swelling) were reported in a small percentage of participants, consistent with other subcutaneous injectable medications. These were generally mild and did not lead to treatment discontinuation.
Serious Adverse Events
Serious adverse events were infrequent and generally not considered related to study treatment. No deaths attributed to retatrutide were reported in Phase 2 trials. The Phase 3 program, with larger patient populations and longer treatment durations, will provide more definitive safety data.
Meta-Analysis Safety Data
A 2025 systematic review and meta-analysis of retatrutide randomized controlled trials confirmed that the drug demonstrated significant improvements in body weight and metabolic outcomes with an appropriate safety profile. The analysis noted that GI adverse events were the most common but were generally manageable and consistent with the incretin-based drug class [4].
What We Don't Know Yet
Several important safety questions remain to be answered by ongoing Phase 3 trials:
> Related Comparison: Ozempic vs Mounjaro: Complete Comparison
References
---
> Take the next step in your optimization journey. If you're ready to move beyond research and into a supervised protocol, Telegenix offers physician-guided peptide and TRT programs with full lab support. Book a free consultation today.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy.
---